University of Chicago at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
University of Chicago takes part in 5 sessions at ESMO 2026 in Madrid. Its program centres on non-small cell lung cancer, from early-stage disease to first-line treatment beyond actionable gene changes, with bispecific antibodies and antibody-drug conjugates in focus. It also presents interim results combining sacituzumab govitecan, enfortumab vedotin and zimberelimab in untreated metastatic urothelial cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
University of Chicago Chicago, IL | |
Private research university in Chicago, Illinois, with a medical school and academic medical centre. | Abstract Fri Oct 23 13:50–14:00 Satellite Sat Oct 24 18:30–20:00 Pfizer - Breaking the Treatment Plateau in Advanced NSCLC: Antibody Therapy Redefined Lung & thoracic cancers Satellite Sat Oct 24 18:30–18:35 Welcome & Introductions Lung & thoracic cancers Satellite Sat Oct 24 18:50–19:15 Bispecifics and ADCs on the Horizon: Evolving the Frontline Standards Lung & thoracic cancers Satellite Sat Oct 24 19:40–19:55 Looking Ahead: The Future Puzzle of aNSCLC Treatment Lung & thoracic cancers Satellite Sun Oct 25 19:10–19:40 Redefining 1L NSCLC: Precision Medicine Beyond Actionable Genomic Alterations Lung & thoracic cancersBiomarkers & precision oncology Chair Mon Oct 26 10:15–11:45 Rapid oral: Non-metastatic NSCLC and other thoracic malignancies Lung & thoracic cancers Abstract Mon Oct 26 11:17–11:29 Invited Discussant 4155RO, 4156RO and 4158RO Lung & thoracic cancers Abstract Mon Oct 26 15:33–15:43 |
Instantly find 20 buyers from University of Chicago
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction